CAR-T therapy for tumors with GD2 or CD70 markers
Part of Cancer clinical trials.
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor is advanced (metastatic, recurring, progressing, or not removable by surgery) after standard first treatment
- Your tumor testing shows GD2 or CD70 are present (from a tissue or blood test)
- You are between 1 and 75 years old, and you weigh at least 10 kg
- You must be able to live at least 8 more weeks, and your overall strength is not too low (Karnofsky score 60% or higher)
- Your heart, lungs, liver, and kidneys have acceptable lab and oxygen levels
- Your blood counts (white cells and platelets) are high enough, and you’re not relying on recent blood/chemo side-effect–related support
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a genetically engineered CAR T-cell treatment called 4SCAR-GD2 for certain solid tumors that have a marker called GD2. It may help shrink tumors that have returned, spread, or can’t be removed with surgery after standard treatment.
This early-phase study tests a custom immune-cell treatment (CAR-T) that targets two tumor markers called GD2 and PSMA. It may help people whose cancer is advanced, cannot be removed with surgery, and has the right marker pattern in their tumor tissue.
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Hear when a new Cancer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.